Lisa Ricciardi, Cognition’s president and CEO, added, “Zervimesine delivered positive clinical data during 2024 from two key Phase 2 studies: the SHIMMER study in DLB and the SHINE study in Alzheimer’s disease. These results show the value that zervimesine holds as we advance towards Phase 3 clinical trials. Looking ahead, we will meet with the FDA on plans to start Phase 3 studies in Alzheimer’s disease and DLB. In parallel, we are actively evaluating options to fund our clinical trials, including potential partnering opportunities with pharmaceutical companies.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Is CGTX a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Cognition Therapeutics publishes research on zervimesine in dry AMD
- Cognition Therapeutics passes pre-defined futility analysis of Phase 2 study
- Cognition VP co-hosting workshop at Neuroimmunology Drug Development Summit
Questions or Comments about the article? Write to editor@tipranks.com